12 research outputs found
Complete Genome Sequence of Mannheimia varigena Isolated from Bovine Milk
peer-reviewedMannheimia varigena is a pathogen of cattle that has been isolated from diseased lung and udder. There are currently complete genome sequences for 4 M. varigena isolates, all from lungs of cattle in the United States. We report a complete genome sequence of M. varigena isolated from bovine milk in Ireland
Assessment of Rapid MinION Nanopore DNA Virus Meta-Genomics Using Calves Experimentally Infected with Bovine Herpes Virus-1
Publication history: Accepted - 20 August 2022; Published - 24 August 2022.Bovine respiratory disease (BRD), which is the leading cause of morbidity and mortality in
cattle, is caused by numerous known and unknown viruses and is responsible for the widespread use
of broad-spectrum antibiotics despite the use of polymicrobial BRD vaccines. Viral metagenomics
sequencing on the portable, inexpensive Oxford Nanopore Technologies MinION sequencer and
sequence analysis with its associated user-friendly point-and-click Epi2ME cloud-based pathogen
identification software has the potential for point-of-care/same-day/sample-to-result metagenomic
sequence diagnostics of known and unknown BRD pathogens to inform a rapid response and vaccine
design. We assessed this potential using in vitro viral cell cultures and nasal swabs taken from calves
that were experimentally challenged with a single known BRD-associated DNA virus, namely, bovine
herpes virus 1. Extensive optimisation of the standard Oxford Nanopore library preparation protocols,
particularly a reduction in the PCR bias of library amplification, was required before BoHV-1 could be
identified as the main virus in the in vitro cell cultures and nasal swab samples within approximately
7 h from sample to result. In addition, we observed incorrect assignment of the bovine sequence to
bacterial and viral taxa due to the presence of poor-quality bacterial and viral genome assemblies in
the RefSeq database used by the EpiME Fastq WIMP pathogen identification software
Resistance génétique aux sarcomes aviaires, resistance anti-virale ou anti-tumorale ?
National audienc
Le polymorphisme du complexe majeur d'histocompatibilité chez le poulet : role du locus Rfp-Y
Résumé de posterNational audienc
Analyse du polymorphisme du complexe majeur d'histocompatibilité dans la lignée de poulets histocompatible B19 : role du locus RFP-Y
National audienc
Le polymorphisme du complexe majeur d'histocompatibilité chez le poulet : role du locus Rfp-Y
National audienc
Analysis of MHC polymorphism in a histocompatible B19 chicken line: role of Rfp-Y locus
International audienc
Role of nonclassical class I genes of the chicken major histocompatibility complex Rfp-Y locus in transplantation immunity
International audienc
Assessment of Rapid MinION Nanopore DNA Virus Meta-Genomics Using Calves Experimentally Infected with Bovine Herpes Virus-1
Bovine respiratory disease (BRD), which is the leading cause of morbidity and mortality in cattle, is caused by numerous known and unknown viruses and is responsible for the widespread use of broad-spectrum antibiotics despite the use of polymicrobial BRD vaccines. Viral metagenomics sequencing on the portable, inexpensive Oxford Nanopore Technologies MinION sequencer and sequence analysis with its associated user-friendly point-and-click Epi2ME cloud-based pathogen identification software has the potential for point-of-care/same-day/sample-to-result metagenomic sequence diagnostics of known and unknown BRD pathogens to inform a rapid response and vaccine design. We assessed this potential using in vitro viral cell cultures and nasal swabs taken from calves that were experimentally challenged with a single known BRD-associated DNA virus, namely, bovine herpes virus 1. Extensive optimisation of the standard Oxford Nanopore library preparation protocols, particularly a reduction in the PCR bias of library amplification, was required before BoHV-1 could be identified as the main virus in the in vitro cell cultures and nasal swab samples within approximately 7 h from sample to result. In addition, we observed incorrect assignment of the bovine sequence to bacterial and viral taxa due to the presence of poor-quality bacterial and viral genome assemblies in the RefSeq database used by the EpiME Fastq WIMP pathogen identification software
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort
International audienceReal-world data (RWD) are essential to complement clinical trial (CT) data, but major challenges remain, such as data quality. REal world dAta in LYmphoma and Survival in Adults (REALYSA) is a prospective noninterventional multicentric cohort started in 2018 that included patients newly diagnosed with lymphoma in France. Herein is a proof-of-concept analysis on patients with first-line diffuse large B-cell lymphoma (DLBCL) to (1) evaluate the capacity of the cohort to provide robust data through a multistep validation process; (2) assess the consistency of the results; and (3) conduct an exploratory transportability assessment of 2 recent phase 3 CTs (POLARIX and SENIOR). The analysis population comprised 645 patients with DLBCL included before 31 March 2021 who received immunochemotherapy and for whom 3589 queries were generated, resulting in high data completeness (<4% missing data). Median age was 66 years, with mostly advanced-stage disease and high international prognostic index (IPI) score. Treatments were mostly rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP 75%) and reduced dose R-CHOP (13%). Estimated 1-year event-free survival (EFS) and overall survival rates were 77.9% and 90.0%, respectively (median follow-up, 9.9 months). Regarding transportability, when applying the CT's main inclusion criteria (age, performance status, and IPI), outcomes seemed comparable between patients in REALYSA and standard arms of POLARIX (1-year progression-free survival 79.8% vs 79.8%) and SENIOR (1-year EFS, 64.5% vs 60.0%). With its rigorous data validation process, REALYSA provides high-quality RWD, thus constituting a platform for numerous scientific purposes. The REALYSA study was registered at www.clinicaltrials.gov as #NCT03869619